WHO ICTRP trial
Immunogenicity and safety study of Rabies G protein Vaccine administered as a…
CTRI/2016/08/007137 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2016/08/007137 |
|---|---|
| Public title | Immunogenicity and safety study of Rabies G protein Vaccine administered as a simulated post-exposure immunization in healthy volunteers |
| Scientific title | Immunogenicity and safety study of Rabies G protein Vaccine administered as a simulated post-exposure immunization in healthy volunteers |
| Primary sponsor | Cadila Pharmaceuticals Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Interventions | Intervention1: Rabies G protein Vaccine (Dose: 50 μg/0.5 ml) Intramuscular Injection once on Day 0, 3 and 7.: Manufactured by Cadila Pharmaceuticals Limited, India Control Intervention1: Rabipur Vaccine (Dose: 2.5 IU/ml, One dose… |
| Registration date | Feb 8, 2016 |
| Target size | 800 |
| Secondary IDs | CRSC15001 Version 3 Dated 12 March 2016 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: